Singapore Technology

Not Yet

Too early to switch out of chip shortage beneficiaries

We continue to be POSITIVE on the Singapore Tech sector on the back of robust end-demand. We continue to prefer beneficiaries of chip shortages (UMS, FRKN, and now AEM) over contract manufacturers with diverse endmarkets (Aztech, VMS, VALUE) as chip shortages still appear a key earnings risk for the latter. Moreover, rotation from the former into the latter appears to have not yet begun. Our top picks are UMS and Frencken on a 3-6 months horizon, and AEM and VMS on a 12 months horizon.

Supply challenges still key bottleneck

Supply side challenges remain the key earnings bottleneck in 2Q21. Several strategies to overcome these include: i) advanced procurement of inventories; ii) reaffirming delivery from suppliers; iii) redesigning components and parts; iv) accelerating vaccine-rates; and v) in the case of UMS and AEM, tapping into the supply chain capabilities of subsidiaries. Chip shortages are generally expected to extend into 2022.

Semicon equipment takeaways

Semicon equipment demand at leading and trailing nodes for logic/ foundry are robust. In trailing nodes, this is powered by a cyclical recovery across multiple end-markets. The buildout in digital infrastructure is also a key demand driver for mature nodes, as sensing devices connected to such infrastructure are typically manufactured out of mature nodes. ASML, AMAT, and Lam Research expect outlook to remain robust through 2022. ASML/ AMAT expects governments' push for fab capacity regionalization in US/Europe to be a catalyst for equipment spend in 2023-24.

Takeaways from VMS' end-markets

VMS' life science and med-tech customers have launched several new products, particularly in liquid chromatography and mass spectrometry an area where VMS is seeing growth. Other domains that customers are optimistic towards include in test & measurement and networking and comms (on strong demand from semicon, 5G-related, and cloud spending) and advanced industrial (infrastructure spending). Amid robust demand drivers, we believe supply side challenges from components shortages and/or capacity restrictions are key risks for the sector.

Analyst	
Analyst	

Gene Lih Lai, CFA (65) 6231 5832 laigenelih@maybank.com

Stock	Bloomberg	MKt Cap	Rating	Price	IP	Upside	P/E	. (X)	P/8	5 (X)	Div y	ld (%)
	code	(USD'm)		(LC)	(LC)	(%)	21E	22E	21E	22E	21E	22E
Venture	VMS SP	4,080	Buy	19.21	25.13	35	16.9	14.1	2.1	1.9	3.9	3.9
AEM Holdings	AEM SP	790	Buy	3.94	5.77	48	14.6	10.8	3.3	2.7	1.7	2.3
Frencken Group	FRKN SP	675	Buy	2.16	2.63	24	14.8	12.7	2.4	2.2	2.0	2.4
UMS Holdings	UMSH SP	645	Buy	1.64	2.10	31	13.1	11.7	3.0	2.5	2.4	2.4
Aztech Global	AZTECH SP	602	Buy	1.06	1.86	78	9.9	7.5	2.9	2.3	2.9	4.0
Valuetronics	VALUE SP	178	Hold	0.56	0.60	11	8.1	9.7	1.1	1.0	5.7	4.1

[Unchanged]


1. Still prefer beneficiaries of chip shortages


Following 2Q21 results season, we remain POSITIVE on the Singapore Tech hardware sector. We continue to prefer beneficiaries of chip shortages (e.g. UMS, Frencken, and now AEM) over contract manufacturers that have exposure to multiple end-markets (e.g. Venture, Aztech, Valuetronics).

We believe a material driver of Frencken and UMS' outperformance YTD (Fig 1) has been due to earnings momentum being stronger than expected (Fig 2). We continue to see potential for Frencken and UMS to positively surprise in the next 1-2 quarters, on the back of still strong demand momentum from customers. The outlook of semiconductor equipment customers (e.g. Applied Materials, ASML, etc) is still buoyant and is expected to remain so in 2022.

AEM has underperformed YTD, with a steep correction in May, particularly driven by guidance that disappointed the market. However, we favour AEM on a 12-month horizon as we expect the company to enter into a new earnings cycle, aided by i) new products and customers; ii) easier base effects in 2022 given the transitory weakness in 1H21; and iii) cyclical factors favouring increasing spend for test equipment.


Thus far, we have not observed rotation from Frencken/ UMS into contract manufacturers like Venture, Aztech and Valuetronics, which may suggest investors are still adopting a "wait-and-see" attitude for the catalysts to manifest. We believe that key rerating catalysts for Aztech, Venture, and Valuetronics are i) delivery of earnings growth; and/ or ii) convincing beats against street estimates, coupled with iii) evidence that end-market outlook remains robust that iv) lead to positive EPS revisions. We see these as catalysts as these should prove that growth bottlenecks from chip shortages are over. Fig 3 shows that VMS' (largest SG-tech hardware stock) share price rallies have typically coincided with positive EPS revision cycles. In contrast, VMS' share price declines have typically led negative EPS revisions.






Source: FactSet

Fig 2: MKE FY21E (Valuetronics: FYMar22E) EPS revisions YTD



Source: Maybank Kim Eng

Fig 3: Historically, VMS' share price rallies have coincided with upward FY1E EPS revisions, while share price declines lead negative EPS revisions




Source: Maybank Kim Eng

2. How are companies tackling supply side challenges

To minimize the adverse impact of supply side disruptions, companies are implementing strategies such as i) advanced procurement of inventories, ii) reaffirming suppliers' delivery commitments, iii) redesigning circuitry and using alternative components; iv) speeding up vaccinations; v) leveraging support from blue-chip customers, and in certain instances, vi) leveraging subsidiaries for capacity/ supply chain expertise.

Companies remain cautious on component availability. Aztech believes that the components shortage situation is unlikely to abate in the next 6-12 months. According to Susquehanna, chip wait times are now more than 20 weeks, the highest it has been since the firm tracked this metric since 2017.

Fig 4: Chip wait times have progressively lengthened this year



Source: Susquehanna Financial Group, Bloomberg

Fig 5: How are SG tech companies overcoming supply side challenges

	Key supply side challenge(s)	Mitigating measures/ factors
Venture	i) Components availability ii) Worker capacity restrictions in Malaysia	 i) Applying various strategies, e.g. going to stockists, advanced procurement of components, or using alternative components ii) Speeding up vaccination rates. VMS aims to have 80% of Malaysia-based employees receive 1st dose by 3Q21. iii) Implement additional shifts to get around worker capacity limits in Malaysia
AEM	i) Supply chain challenges as a result of Covid-19 situation in Malaysia	 i) AEM is working with suppliers to secure adequate parts and components. CEI also has a good supply chain team that helps during supply crunch. AEM has high confidence of being able to deliver customer requirements at least for 2H21. ii) Implement additional shifts to get around worker capacity limits in Malaysia
UMS	i) Production capacity, especially on the back of strong of strong demand, and worker capacity restrictions	 i) Acquisition of JEP provides capacity for semicon components ii) In Penang, worker capacity limits is now eased to 80% from 60%, which should alleviate some tightness. Implement additional shifts to get around worker capacity limits in Malaysia iii) UMS does not face inventory shortages, as distribution arm Starke is able to ensure sufficiency for UMS' needs.
Frencken	 i) Sees components shortages impacting supply chains in quite a few end-markets it is exposed to 	i) Anticipating semiconductor and automotive revenue to be flat HoH in 2H21, with upside if components shortages ease in these supply chains.ii) Notwithstanding shortages in the supply chain, Frencken sees medical and analytical revenues to be stronger HoH in 2H21.
Aztech	i) Components availability ii) Worker capacity restrictions in Malaysia	 i) Secure delivery commitments of components for 2H21 requirements ii) Redesign parts and components for certain products iii) Advanced procurement where necessary iv) Transferred some of the allocation from Malaysia to China.

Source: Maybank Kim Eng

3. Semicon takeaways

3.1 AEM - Positive read-across from Intel's actions

AEM reiterated that new generation tools for Intel will undergo mass production in late 3Q21 through 2022. In that regard, AEM expects 2H21 uptake to be strong following 1H21 transitory weakness. We are excited with AEM's earnings prospects in 2022, given some of the corroborating factors below.

AEM believes its addressable market will benefit from additional investments in back-end test in the subsequent quarters, following strong capex from front-end players (e.g. Intel/ foundry players). To handle new demands by Intel's customers and to speed up the ramp for assembly and test operations, Intel is investing USD600m in Costa Rica (up from USD350m in Dec-20). Separately, Buletin Mutiara (Penang government-affiliated news site) announced in Jun-21 that Intel will invest MYR4.4b (USD1.04b) in Penang.

In the 17 months leading up to Jan-21, Intel invested USD475m in Vietnam (assembly and test site). Coincidentally in 2020, AEM's revenue from Vietnam rose 75% YoY to SGD140.2m, accounting for 27% of revenue. As we believe the proposition of AEM's equipment remains very relevant to Intel, we do not rule out that the expansion of assembly and test capacity in Costa Rica and Penang are corroborative factors for AEM's growth in the near term.

Fig 6: AEM's revenue by geography

57

2017

2018



In 2020, amid Intel's expansion in Vietnam, AEM's Vietnam revenue rose 75% YoY

Source: Company

200

100

0

In the past, AEM's growth has also coincided with Intel's node migrations. For instance, in 2019, AEM's revenue grew 23% as Intel transitioned to 10nm. The reason why we believe major node migrations at Intel are positive for AEM is because at new nodes, chips require more testing to ensure reliability, until such time that engineers are familiar with the node. Intel's next major node migration is to Intel 4 (formerly "7nm"), with production set for 2H22 and the first four products planned for 2023 (Meteor Lake for consumer products, and Granite Rapids for data centres).


2019

Singapore Malaysia China USA Vietnam Costa Rica Others

2020

1H21

Fig 7: Intel's technology node roadmap



Source: Intel

In Intel's Jul-21 update on process and packaging innovations, it reiterated its commitment to advanced packaging technologies such as EMIB (embedded multi-die interconnect bridge), and Foveros 3D stack. We see this trend is beneficial for AEM as we do not rule out that in addition to current equipment, new generations of equipment from AEM could be used to address test complexities as a result of advanced packaging technologies. For instance, in the case of 3D logic stack, interconnects must be adequately tested for thermal reliability, and AEM believes it has the best active thermal control capability to accurately and speedily test for thermal reliability. Moreover, Intel's chips are often highly mission critical, with parts per billion requirements to ensure no product failure or recall.

3.2 Takeaways from wafer fab equipment (WFE) customers

ASML believes that the current shortages were in part result of supply chains' cautiousness at start of Covid-19 and sees the current cyclical catch up in chip demand to persist into next year. Meanwhile AMAT sees WFE spending being >USD80b (i.e. growth >30%) in 2021, and expects WFE to be higher in 2022, across logic/foundry, DRAM and NAND segments.

ASML and Applied Materials continue to note strong demand momentum in logic/ foundry. In memory, ASML notes tight supply-demand dynamics, while AMAT cites that DRAM/ NAND inventory levels are below normal/ normal respectively.

Several themes have also been mentioned:

- Long-term demand driven by digital infrastructure buildout: In logic/foundry, strength is observed in both leading and trailing nodes. In trailing nodes, ASML attributes the strength of long-term demand to the buildout of digital infrastructure as 5G and edge computing takes off. For instance, while compute at the edge is typically done on advanced chips, sensing devices that are connected to them are typically manufactured from mature nodes.
- Regionalisation of fab capacity: Amid the realization of over-reliance on North Asian fabs, countries are now pushing to regionalize fab capacity to diversify geographical risks. ASML and AMAT expects spending from such initiatives to take place more towards the 2023-24 timeframe. The implication of this is likely higher demand for semicon

equipment, as the regionalisation of fab capacity will likely create inefficiency in the semiconductor supply chain.

Capacity expansion by WFE players and supply chain. ASML, AMAT, and Lam are actively expanding capacity. On the back of robust demand, ASML is actively working with the supply chain to increase capacity. We understand some of Frencken's (ASML is customer) capacity addition also caters for semicon. While ASML is expanding capacity in the immediate horizon and for the long-term, it specifies that its capacity expansion plans are focused on long-term demand. ASML also reiterates that it has long-term demand commitments from its customers. This is because tools built by ASML are highly specialized for semiconductor manufacturing, and overcapacity and high inventory levels could result in large obsolescence and losses unless capacity is managed with discipline. Lam Research have shipped out the first equipment built at the new Penang plant, and we continue to think Lam's supply chain buildout may benefit contract manufacturers and precision-engineering players in Malaysia/ Singapore. Meanwhile, UMS notes that the consolidation of JEP provides it access to capacity amid strong order flows from customer Applied Materials.

4. Takeaways from Venture's end-markets

VMS remains optimistic of the demand outlook over the next 12 months. Across seven domains, broad-based strength is observed, with the exception of one (i.e. financial technology). In particular, life-science and medical technology customers are benefitting from strong pharma and biotech endmarkets amid the current battle against Covid-19.

VMS highlighted liquid chromatography and mass spectrometry as a key growth area. These were areas where customers like Agilent and Thermo Fisher are launching new products. VMS' customers were also optimistic in test & measurement, networking and communications, advanced industrials and semiconductor-related equipment verticals.

Fig 8: Overview of VMS' end-markets

Ecosystem domain	E.g. customers	Outlook from latest available earnings/ conference transcripts/ media	Customers' mentions of new products (VMS may or may not be involved)	Overall tone
 Life Science & Instrumentation Medical Technology & Healthcare 	Agilent, Thermo Fisher, Illumina, Waters, PerkinElmer, Keysight, Fortive	Life sciences and med tech - Many companies raised FY21 outlook. Broad-based strength observed across end- markets, with the strongest stemming from pharma and biotech (still driven by Covid-19-related demand). Academic and government, and industrial and applied markets are also robust. End-demand strength is driven by the industry's role in combating the pandemic and strong economic activity globally. Illumina is seeing the highest order volume for Novaseq since launch in 2017 (high-throughput). Demand momentum for mid and low throughput are also very robust. Illumina's NextSeq 2000 mid-throughput platform is enabling new applications in single cell analysis. Customers see conducive environment to launch new products. Instrumentation: Thermo Fisher, PerkinElmer and Keysight notes robust semicon activity. In particular, Keysight expects semicon capacity expansions to last into 2022, and upside to long-term forecasts would be regional fab capacity expansions in Europe and US. Keysight is also a beneficiary of global 5G deployments and the rollout of 5G chipsets, ORAN adoption, 400- gigabit and 800-gigabit ethernet for data centres.	Agilent: Launched 3 InfinityLab Bio - LC Systems (LC stands for liquid chromatography), LC/Q - TOF and LC -TOF solutions. LC/Q - TOF refers to quadropole time of flight liquid chromatography/ mass spectrometry. Thermo Fisher: Thermo Scientific Orbitrap IQX Tribrid mass spectrometer; Thermo Scientific Helios 5EXL wafer dual beam scanning electron microscope (for semicon), Invitrogen Bigfoot Spectral Sorter and Invitrogen Attune CytPix Flow Spectrometer for cell analysis.	Positive
• RF & Communication	Broadcom, Marvell, Lumentum	Broadband and networking bookings are strong, from hypercloud and service providers. Broadcom was also a beneficiary of 5G infrastructure rollout globally. Marvell expects strong 2H21 ramp as compared to 1H for its networking business, from own product ramps and increase in 5G adoption in US and other regions. Lumentum has high backlog from strong demand for its products as cloud datacentres transition to 200-gigabit and 400-gigabit speeds. Lumentum's book-to-bill was 1.2x in the most recent quarter.		Positive
• Financial Technology	NCR, Ingenico	NCR's 2Q21 standalone revenue rose 11% YoY, and hardware revenue grew 20.5% YoY. Retail hardware was strong in 2Q21, but that was due to a pull-in from a customer for a delivery otherwise slated for 3Q21. ATM hardware faced challenges. As hardware was severely impacted in 2020 amid Covid-19-related disruptions, NCR notes pent up demand.		Cautiously optimistic
• Consumer / Lifestyle	Philip Morris	Philip Morris to launch IQOS ILUMA, first in Japan, and subequently in other markets in 2H21. Over time, Philip Morris intends to transition beyond a nicotine strategy to other inhalable products. Philip Morris believes recent acquisitions Fertin and Vectura would help with these.	IQOS ILUMA	Positive
 Advanced Industrial Others 	ABB, Honeywell, HP Inc	ABB and Honeywell raised FY21 outlook. and observes that sourcing environment for direct materials and components has been very tight. Honeywell's buildings and infrastructure end-markets are a beneficiary of fiscal stimulus and infrastructure spending plans in the US and globally. Honeywell sees strong 2022 set-up and beyond.		Positive


Source: Various companies, Maybank Kim Eng


Maybank Kim Eng

Fig 9: Sales growth outlook of VMS' customers

		Sales growth (%)					
	CY21E		CY22E	CY23E			
Venture (consensus)		7%	8%	4%			
ABB		13%	5%	4%			
Agilent		18%	7%	6%			
Broadcom		14%	6%	4%			
Honeywell		8%	8%	6%			
Fortive		15%	5%	6%			
HP Inc		12%	-1%	-1%			
Illumina		33%	11%	14%			
Keysight		16%	5%	6%			
NCR		17%	12%	3%			
Marvell		0%	42%	19%			
Lumentum		-1%	0%	11%			
Thermo Fisher		12%	0%	6%			
Waters		16%	5%	5%			
Philip Morris		9%	6%	6%			
Royal Philips		-10%	7%	5%			
PerkinElmer		21%	-14%	7%			
Medtronic		0%	10%	5%			
Average ex-VMS		11%	7%	7%			

Source: Bloomberg





Source: Bloomberg

Research Offices

ECONOMICS

Suhaimi ILIAS Chief Economist Malaysia | Philippines | Global (603) 2297 8682 suhaimi_ilias@maybank-ib.com

CHUA Hak Bin Regional Thematic Macroeconomist (65) 6231 5830 chuahb@maybank.com

LEE Ju Ye Singapore | Thailand | Indonesia (65) 6231 5844 leejuye@maybank.com

Linda LIU Singapore | Vietnam | Cambodia | Myanmar | Laos (65) 6231 5847 lindaliu@maybank.com

Dr Zamros DZULKAFLI (603) 2082 6818 zamros.d@maybank-ib.co

Ramesh LANKANATHAN (603) 2297 8685 ramesh@maybank-ib.com

FΧ

Saktiandi SUPAAT Head of FX Research (65) 6320 1379 saktiandi@mavbank.com.sg

Christopher WONG (65) 6320 1347 wongkl@maybank.com.sg

TAN Yanxi (65) 6320 1378 tanyx@maybank.com.sg

Fiona LIM (65) 6320 1374 fionalim@maybank.com.sg

STRATEGY

Anand PATHMAKANTHAN ASEAN (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

FIXED INCOME

Winson PHOON, ACA (65) 6340 1079 winsonphoon@maybank.com

SE THO Mun Yi (603) 2074 7606 munyi.st@maybank-ib.com REGIONAL EQUITIES

Anand PATHMAKANTHAN Head of Regional Equity Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

WONG Chew Hann, CA Head of ASEAN Equity Research (603) 2297 8686 wchewh@maybank-ib.com

ONG Seng Yeow Research, Technology & Innovation (65) 6231 5839 ongsengyeow@maybank.com

MALAYSIA

Anand PATHMAKANTHAN Head of Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com • Strategy

WONG Chew Hann, CA (603) 2297 8686 wchewh@maybank-ib.com • Non-Bank Financials (stock exchange) • Construction & Infrastructure

Desmond CH'NG, BFP, FCA (603) 2297 8680 desmond.chng@maybank-ib.com • Banking & Finance

LIAW Thong Jung (603) 2297 8688 tjliaw@maybank-ib.com • Oil & Gas Services- Regional • Automotive

ONG Chee Ting, CA (603) 2297 8678 ct.ong@maybank-ib.com • Plantations - Regional

YIN Shao Yang, CPA (603) 2297 8916 samuel.y@maybank-ib.com • Gaming - Regional • Media • Aviation • Non-Bank Financials

TAN Chi Wei, CFA (603) 2297 8690 chiwei.t@maybank-ib.com • Power • Telcos

WONG Wei Sum, CFA (603) 2297 8679 weisum@maybank-ib.com • Property • Glove

Kevin WONG (603) 2082 6824 kevin.wong@maybank-ib.com • REITs • Technology

Jade TAM (603) 2297 8687 jade.tam@maybank-ib.com • Consumer Staples & Discretionary

Fahmi FARID (603) 2297 8676 fahmi.farid@maybank-ib.com • Software

Syifaa' Nur FARAH (603) 2297 8675 nurfarahsyifaa.mohamadfuad@maybank-ib.com • Construction

Arvind JAYARATNAM (603) 2297 8692 arvind.jayaratnam@maybank.com • Ports • Shipping • Petrochemicals

TEE Sze Chiah Head of Retail Research (603) 2082 6858 szechiah.t@maybank-ib.com

Nik Ihsan RAJA ABDULLAH, MSTA, CFTe (603) 2297 8694 nikmohdihsan.ra@maybank-ib.com • Chartist

Amirah AZMI (603) 2082 8769 amirah.azmi@maybank-ib.com • Retail Research

SINGAPORE

Thilan WICKRAMASINGHE Head of Research (65) 6231 5840 thilanw@maybank.com • Banking & Finance - Regional • Consumer

CHUA Su Tye (65) 6231 5842 chuasutye@maybank.com • REITs - Regional

LAI Gene Lih, CFA (65) 6231 5832 laigenelih@maybank.com • Technology • Healthcare

Kareen CHAN (65) 6231 5926 kareenchan@maybank.com • Transport • Telcos • Consumer

Eric ONG (65) 6231 5924 ericong@maybank.com • SMIDs

Matthew SHIM (65) 6231 5929 matthewshim@maybank.com • REITs

PHILIPPINES Jacqui de JESUS Head of Research (63) 2 8849 8840 jacqui.dejesus@maybank.com • Strategy • Conglomerates

Rachelleen RODRIGUEZ, CFA (63) 2 8849 8843 rachelleen.rodriguez@maybank.com • Banking & Finance • Transport • Telcos

Benedict CLEMENTE (63) 2 8849 8846 benedict.clemente@maybank.com • Utilities

Daphne SZE (63) 2 8849 8847 daphne.sze@maybank.com • Consumer

Banks

VIETNAM Quan Trong Thanh Head of Research (84 28) 44 555 888 ext 8184 thanh.quan@maybank-kimeng.com.vn

Hoang Huy, CFA (84 28) 44 555 888 ext 8181 hoanghuy@maybank-kimeng.com.vn • Strategy • Technology

Le Nguyen Nhat Chuyen (84 28) 44 555 888 ext 8082 chuyen.le@maybank-kimeng.com.vn • Oil & Gas

Nguyen Thi Sony Tra Mi (84 28) 44 555 888 ext 8084 mi.nguyen@maybank-kimeng.com.vn • Consumer

Tyler Manh Dung Nguyen (84 28) 44 555 888 ext 8085 dung.nguyen@maybank-kimeng.com.vn • Utilities • Property

Tran Thi Thu Thao (84 28) 44 555 888 ext 8180 thao.tran@maybank-kimeng.com.vn • Industrials

Nguyen Thi Ngan Tuyen Head of Retail Research (84 28) 44 555 888 ext 8081 tuyen.nguyen@maybank-kimeng.com.vn • Retail Research

Nguyen Thanh Lam (84 28) 44 555 888 ext 8086 thanhlam.nguyen@maybank-kimeng.com.vn • Technical Analysis

INDIA

Jigar SHAH Head of Research (91) 22 4223 2632 jigars@maybank.com • Strategy • Oil & Gas • Automobile • Cement

Neerav DALAL (91) 22 4223 2606 neerav@maybank.com • Software Technology • Telcos

Vikram RAMALINGAM (91) 22 4223 2607 vikram@maybank.com • Automobile • Media

INDONESIA

Rahmi MARINA (62) 21 8066 8689 rahmi.marina@maybank-ke.co.id • Banking & Finance

Willy GOUTAMA (62) 21 8066 8500 willy.goutama@maybank-ke.co.id • Consumer

Farah OKTAVIANI (62) 21 8066 8691 farah.oktaviani@maybank-ke.co.id • Construction

THAILAND

Maria LAPIZ Head of Institutional Research Dir (66) 2257 0250 | (66) 2658 6300 ext 1399 Maria.L@maybank-ke.co.th • Strategy • Consumer • Materials • Services

Jesada TECHAHUSDIN, CFA (66) 2658 6300 ext 1395 jesada.t@maybank-ke.co.th • Banking & Finance

Kaushal LADHA, CFA, CESGA (66) 2658 6300 ext 1392 Kaushal.l@maybank-ke.co.th • Oil & Gas - Regional • Petrochemicals - Regional • Utilities

Vanida GEISLER, CPA (66) 2658 6300 ext 1394 Vanida.G@maybank-ke.co.th • Property • REITs

Yuwanee PROMMAPORN (66) 2658 6300 ext 1393 Yuwanee.P @maybank-ke.co.th • Services • Healthcare

Ekachai TARAPORNTIP Head of Retail Research (66) 2658 5000 ext 1530 Ekachai.t@maybank-ke.co.th

Surachai PRAMUALCHAROENKIT (66) 2658 5000 ext 1470 Surachai.p@maybank-ke.co.th • Auto • Conmat • Contractor • Steel

Suttatip PEERASUB (66) 2658 5000 ext 1430 suttatip.p@maybank-ke.co.th • Food & Beverage • Commerce

Jaroonpan WATTANAWONG (66) 2658 5000 ext 1404 jaroonpan.w@maybank-ke.co.th • Transportation • Small cap

Thanatphat SUKSRICHAVALIT (66) 2658 5000 ext 1401 thanaphat.s@maybank-ke.co.th • Media • Electronics

Wijit ARAYAPISIT (66) 2658 5000 ext 1450 wijit.a@maybank-ke.co.th • Strategist

Theerasate PROMPONG (66) 2658 5000 ext 1400 theerasate.p@maybank-ke.co.th • Equity Portfolio Strategist

Apiwat TAVESIRIVATE

(66) 2658 5000 ext 1310

apiwat.t@maybank-ke.co.th

Chartist and TFEX

APPENDIX I: TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

DISCLAIMERS

This research report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. Investors should note that values of such securities, if any, may fluctuate and that each security's price or value may rise or fall. Opinions or recommendations contained herein are in form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from the relevant jurisdiction's stock exchange in the equity analysis. Accordingly, investors' returns may be less than the original sum invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Maybank Investment Bank Berhad, its subsidiary and affiliates (collectively, "MKE") and consequently no representation is made as to the accuracy or completeness of this report by MKE and it should not be relied upon as such. Accordingly, MKE and its officers, directors, associates, connected parties and/or employees (collectively, "Representatives") shall not be liable for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Any information, opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. MKE expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

MKE and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. One or more directors, officers and/or employees of MKE may be a director of the issuers of the securities mentioned in this report to the extent permitted by law.

This report is prepared for the use of MKE's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of MKE and MKE and its Representatives accepts no liability whatsoever for the actions of third parties in this respect.

This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. This report is for distribution only under such circumstances as may be permitted by applicable law. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

Malaysia

Opinions or recommendations contained herein are in the form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from Bursa Malaysia Securities Berhad in the equity analysis.

Singapore

This report has been produced as of the date hereof and the information herein may be subject to change. Maybank Kim Eng Research Pte. Ltd. ("Maybank KERPL") in Singapore has no obligation to update such information for any recipient. For distribution in Singapore, recipients of this report are to contact Maybank KERPL in Singapore in respect of any matters arising from, or in connection with, this report. If the recipient of this report is not an accredited investor, expert investor or institutional investor (as defined under Section 4A of the Singapore Securities and Futures Act), Maybank KERPL shall be legally liable for the contents of this report, with such liability being limited to the extent (if any) as permitted by law.

Thailand

Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Maybank Kim Eng Securities (Thailand) Public Company Limited ("MBKET") accepts no liability whatsoever for the actions of third parties in this respect.

Due to different characteristics, objectives and strategies of institutional and retail investors, the research products of MBKET Institutional and Retail Research departments may differ in either recommendation or target price, or both. MBKET reserves the rights to disseminate MBKET Retail Research reports to institutional investors who have requested to receive it. If you are an authorised recipient, you hereby tacitly acknowledge that the research reports from MBKET Retail Research are first produced in Thai and there is a time lag in the release of the translated English version.

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey may be changed after that date. MBKET does not confirm nor certify the accuracy of such survey result.

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, MBKET does not confirm, verify, or certify the accuracy and completeness of the assessment result.

US

This third-party research report is distributed in the United States ("US") to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Maybank Kim Eng Securities USA Inc ("Maybank KESUSA"), a broker-dealer registered in the US (registered under Section 15 of the Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Maybank KESUSA in the US shall be borne by Maybank KESUSA. This report is not directed at you if MKE is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Maybank KESUSA is permitted to provide research material concerning investments to you under relevant legislation and regulations. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security mentioned within must do so with: Maybank Kim Eng Securities USA Inc. 400 Park Avenue, 11th Floor, New York, New York 10022, 1-(212) 688-8886 and not with, the issuer of this report.

UK

This document is being distributed by Maybank Kim Eng Securities (London) Ltd ("Maybank KESL") which is authorized and regulated, by the Financial Conduct Authority and is for Informational Purposes only. This document is not intended for distribution to anyone defined as a Retail Client under the Financial Services and Markets Act 2000 within the UK. Any inclusion of a third party link is for the recipients convenience only, and that the firm does not take any responsibility for its comments or accuracy, and that access to such links is at the individuals own risk. Nothing in this report should be considered as constituting legal, accounting or tax advice, and that for accurate guidance recipients should consult with their own independent tax advisers.

DISCLOSURES

Legal Entities Disclosures

Malaysia: This report is issued and distributed in Malaysia by Maybank Investment Bank Berhad (15938- H) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets and Services License issued by the Securities Commission in Malaysia. Singapore: This report is distributed in Singapore by Maybank KERPL (Co. Reg No 198700034E) which is regulated by the Monetary Authority of Singapore. Indonesia: PT Maybank Kim Eng Securities ("PTMKES") (Reg. No. KEP-251/PM/1992) is a member of the Indonesia Stock Exchange and is regulated by the Financial Services Authority (Indonesia). Thailand: MBKET (Reg. No.0107545000314) is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. Philippines: Maybank ATRKES (Reg. No.01-2004-00019) is a member of the Philippines Stock Exchange and is regulated by the Securities and Exchange Commission. Vietnam: Maybank Kim Eng Securities Limited (License Number: 117/GP-UBCK) is licensed under the State Securities Commission of Vietnam. Hong Kong: KESHK (Central Entity No AAD284) is regulated by the Securities and Exchange Board of India ("SEBI") (Reg. No. INZ000010538). KESI is also registered with SEBI as Category 1 Merchant Banker (Reg. No. INM 000011708) and as Research Analyst (Reg No: INH000000057) US: Maybank KESUSA is a member of / and is authorized and regulated by the FINRA - Broker ID 27861. UK: Maybank KESL (Reg No 2377538) is authorized and regulated by the Financial Conduct Authority.

Disclosure of Interest

Malaysia: MKE and its Representatives may from time to time have positions or be materially interested in the securities referred to herein and may further act as market maker or may have assumed an underwriting commitment or deal with such securities and may also perform or seek to perform investment banking services, advisory and other services for or relating to those companies.

Singapore: As of 23 August 2021, Maybank KERPL and the covering analyst do not have any interest in any companies recommended in this research report.

Thailand: MBKET may have a business relationship with or may possibly be an issuer of derivative warrants on the securities /companies mentioned in the research report. Therefore, Investors should exercise their own judgment before making any investment decisions. MBKET, its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the securities mentioned in this report.

Hong Kong: As of 23 August 2021, KESHK and the authoring analyst do not have any interest in any companies recommended in this research report.

India: As of 23 August 2021, and at the end of the month immediately preceding the date of publication of the research report, KESI, authoring analyst or their associate / relative does not hold any financial interest or any actual or beneficial ownership in any shares or having any conflict of interest in the subject companies except as otherwise disclosed in the research report.

In the past twelve months KESI and authoring analyst or their associate did not receive any compensation or other benefits from the subject companies or third party in connection with the research report on any account what so ever except as otherwise disclosed in the research report.

MKE may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment and may receive compensation for the services provided from the companies covered in this report.

OTHERS

Analyst Certification of Independence

The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

Reminder

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without the prior consent of MKE.

Definition of Ratings

Maybank Kim Eng Research uses the following rating system

- BUY Return is expected to be above 10% in the next 12 months (including dividends)
- HOLD Return is expected to be between 0% to 10% in the next 12 months (including dividends)
- SELL Return is expected to be below 0% in the next 12 months (including dividends)

Applicability of Ratings

The respective analyst maintains a coverage universe of stocks, the list of which may be adjusted according to needs. Investment ratings are only applicable to the stocks which form part of the coverage universe. Reports on companies which are not part of the coverage do not carry investment ratings as we do not actively follow developments in these companies.

👩 Malaysia

Maybank Investment Bank Berhad (A Participating Organisation of Bursa Malaysia Securities Berhad) 33rd Floor, Menara Maybank, 100 Jalan Tun Perak, 50050 Kuala Lumpur Tel: (603) 2059 1888; Fax: (603) 2078 4194

Stockbroking Business: Level 8, Tower C, Dataran Maybank, No.1, Jalan Maarof 59000 Kuala Lumpur Tel: (603) 2297 8888 Fax: (603) 2282 5136

Philippines

Maybank ATR Kim Eng Securities Inc. 17/F, Tower One & Exchange Plaza Ayala Triangle, Ayala Avenue Makati City, Philippines 1200

Tel: (63) 2 8849 8888 Fax: (63) 2 8848 5738

South Asia Sales Trading

Kevin Foy Regional Head Sales Trading kevinfoy@maybank-ke.com.sg Tel: (65) 6636-3620 US Toll Free: 1-866-406-7447

Indonesia Iwan Atmadjaja iatmadjaja2@bloomberg.net (62) 21 8066 8555

New York James Lynch jlynch@maybank-keusa.com Tel: (212) 688 8886

Philippines Keith Roy keith_roy@maybank-atrke.com Tel: (63) 2 848-5288

📀 Singapore

Maybank Kim Eng Securities Pte Ltd Maybank Kim Eng Research Pte Ltd 50 North Canal Road Singapore 059304

Tel: (65) 6336 9090

📀 Hong Kong

Kim Eng Securities (HK) Ltd 28/F, Lee Garden Three, 1 Sunning Road, Causeway Bay, Hong Kong

Tel: (852) 2268 0800 Fax: (852) 2877 0104

👩 Thailand

Maybank Kim Eng Securities (Thailand) Public Company Limited 999/9 The Offices at Central World, 20th - 21st Floor, Rama 1 Road Pathumwan, Bangkok 10330, Thailand

Tel: (66) 2 658 6817 (sales) Tel: (66) 2 658 6801 (research)

North Asia Sales Trading

Andrew Lee andrewlee@kimeng.com.hk Tel: (852) 2268 0283 US Toll Free: 1 877 837 7635

London Greg Smith gsmith@maybank-ke.co.uk Tel: (44) 207-332-0221

India Sanjay Makhija sanjaymakhija@maybank-ke.co.in Tel: (91)-22-6623-2629

🐔 London

Maybank Kim Eng Securities (London) Ltd PNB House 77 Queen Victoria Street London EC4V 4AY, UK

Tel: (44) 20 7332 0221 Fax: (44) 20 7332 0302

🌏 Indonesia

PT Maybank Kim Eng Securities Sentral Senayan III, 22nd Floor Jl. Asia Afrika No. 8 Gelora Bung Karno, Senayan Jakarta 10270, Indonesia

Tel: (62) 21 2557 1188 Fax: (62) 21 2557 1189

🌏 Vietnam

Maybank Kim Eng Securities Limited 4A-15+16 Floor Vincom Center Dong Khoi, 72 Le Thanh Ton St. District 1 Ho Chi Minh City, Vietnam

Tel : (84) 844 555 888 Fax : (84) 8 38 271 030

👩 New York

Maybank Kim Eng Securities USA Inc 400 Park Avenue, 11th Floor New York, New York 10022, U.S.A.

Tel: (212) 688 8886 Fax: (212) 688 3500

🌏 India

Kim Eng Securities India Pvt Ltd 1101, 11th floor, A Wing, Kanakia Wall Street, Chakala, Andheri -Kurla Road, Andheri East, Mumbai City - 400 093, India

Tel: (91) 22 6623 2600 Fax: (91) 22 6623 2604

Saudi Arabia

In association with Anfaal Capital Ground Floor, KANOO Building No.1 - Al-Faisaliyah,Madina Road, P.O.Box 126575 Jeddah 21352 Kingdom of Saudi Arabia

Tel: (966) 920023423

www.maybank-ke.com | www.maybank-keresearch.com